title: Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus.
abstract: Mammalian target of rapamycin inhibitor everolimus is a novel agent used in endocrine therapy resistant hormone receptor positive metastatic breast cancer. Its use has been associated with clinically significant improvement in the otherwise dismal outcomes of this subset of patients. Rash is a common adverse effect associated with everolimus. However, Hand-foot syndrome is an uncommon toxicity with the use of this drug. We report a case of Grade 3 hand-foot syndrome following institution of everolimus therapy and describe its successful management.
authors.affiliation: Department of Medical Oncology, Christian Medical College Hospital, Vellore, Tamil Nadu, India.
authors.forename: Shalabh
authors.initials: S
authors.lastname: Arora
authors.affiliation: Department of Medical Oncology, Christian Medical College Hospital, Vellore, Tamil Nadu, India.
authors.forename: Rajendra
authors.initials: R
authors.lastname: Akhil
authors.affiliation: Department of Medical Oncology, Christian Medical College Hospital, Vellore, Tamil Nadu, India.
authors.forename: Raju Titus
authors.initials: RT
authors.lastname: Chacko
authors.affiliation: Department of Dermatology, Venereology and Leprosy, Christian Medical College Hospital, Vellore, Tamil Nadu, India.
authors.forename: Renu
authors.initials: R
authors.lastname: George
keywords: Breast cancer; everolimus; hand-foot syndrome; mammalian target of rapamycin inhibitors; palmar-plantar erythrodysesthesia